Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/20/2783626/0/en/Aerovate-Therapeutics-Announces-Simultaneous-Completion-of-Enrollment-in-Phase-2b-Portion-and-Enrollment-of-First-Patient-into-Phase-3-in-the-IMPAHCT-Trial-Evaluating-AV-101-for-th.html

Topline Phase 2b data expected in June 2024

More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial

Read more at globenewswire.com

Related news for (AVTE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.